Table 3.
Comorbidities and BCVA
| Characteristics | Improved BCVA | Worse BCVA | Unchanged BCVA | p value |
|---|---|---|---|---|
| Gender: M/F | 56/47 | 29/16 | 12/12 | 0.4154 |
| Type 1 DM/Type 2DM | 9/94 | 11/34 | 2/22 | 0.0244 |
| HBP: yes/no | 84/19 | 33/12 | 18/6 | 0.4832 |
| Stroke: yes/no | 7/96 | 5/40 | 1/23 | 0.5236 |
| Heart disease: yes/no | 37/66 | 12/33 | 4/20 | 0.1439 |
| Dyslipidemia: yes/no | 31/72 | 15/30 | 4/20 | 0.3262 |
| Neuropathy: yes/no | 19/84 | 5/40 | 4/20 | 0.5380 |
| Nephropathy: yes/no | 11/92 | 8/37 | 2/32 | 0.2397 |
| Antiplatelet drugs: yes/no | 32/71 | 13/32 | 6/18 | 0.8350 |
| Insulin: yes/no | 90/13 | 35/10 | 17/7 | 0.0969 |
| Oral antidiabetic drugs | 29/29 | 39/18 | 11/11 | 0.0989 |
M= male; F= female; DM= Diabetes mellitus; HBP= High blood pressure; BCVA= best corrected visual acuity.
The italicized p values indicate a statistically significant difference between groups.